Pharma deals value decreases by 14.8 per cent in August 2022: GlobalData

Pharma industry reported 55 deals worth $12.5 billion as compared to the last 12-month average (August 2021 to July 2022) of 76 deals worth $12.3 billion, the latest report from GlobalData has revealed.

Pfizer to acquire all outstanding shares of Global Blood Therapeutics for a total enterprise value of approximately $5.4 billion, including debt and net cash; Amgen to acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion; and Alcon to acquire Aerie Pharma for an enterprise value of approximately $1 billion were the three major deals that contributed 80.8 per cent of the total deal value during August 2022, the report mentioned.

It also said that the industry reported 120 Venture Capital (VC) deals worth $2.6 billion in August 2022, compared to the last 12-month average (August 2021 to July 2022) of 154 deals worth $4.1 billion.

Orna Therapeutics raising $221 million in series B round of financing to continue development of its circular RNA + LNP (lipid nanoparticle) delivery platform; Sironax raising $200 million in series B round of financing to support pipeline progression and expansion for age-related degenerative diseases; Senda Biosciences raising $123 million in series C round of financing to drive further development of its proprietary programmable medicines platform and advance its first programmes into clinical testing were the major VC deals reported in August 2022, concluded the statement.